Policy & Insights

Strategic pillars | Clinical practice guidelines & position papers | Publications | Expert commentary

From publications and consensus statements to regional and global policy briefs, this section gathers essential materials to advise research and action priorities for SLD, with a focus on MASLD/MASH. It also showcases commentaries from professionals and those with lived experiences, offering timely insights into the challenges and opportunities across liver and metabolic health fields.

Strategic pillars

Frameworks and policy briefs for local, national and global action

Global agendas

Global Metabolic & Liver Health Policy

Global Metabolic & Liver Health Policy

Detecting at-risk steatotic liver disease and liver fibrosis in the community
Adams, L. A., Thiele, M., & Tsochatzis, E. A.

Hepatology ():10.1097/HEP.0000000000001400, May 16, 2025.

10.1097/HEP.0000000000001400
Global Metabolic & Liver Health Policy

Global Metabolic & Liver Health Policy

A global research priority agenda to advance public health responses to fatty liver disease
Lazarus, Jeffrey V. et al.

Journal of Hepatology, Volume 79, Issue 3, 618 - 634

http://doi.org/10.1016/j.jhep.2023.04.035
Global Metabolic & Liver Health Policy

Global Metabolic & Liver Health Policy

A global action agenda for turning the tide on fatty liver disease
Lazarus, Jeffrey V. et al.

Hepatology 79(2):p 502-523, February 2024.

10.1097/HEP.0000000000000545

See all

Regional snapshots

Public Health & Clinical Best Practices

Public Health & Clinical Best Practices

MASLD/MASH in Spain: A liver health policy brief

See all

Briefing notes

Global Metabolic & Liver Health Policy

Global Metabolic & Liver Health Policy

Chronic Liver Disease, MASLD/MASH, and the Global NCD Agenda

See all

Clinical practice guidelines & position papers

Unified expert perspectives on liver and metabolic health

Public Health & Clinical Best Practices

Public Health & Clinical Best Practices

The People-first Liver Charter
Lazarus, J.V., Ivancovsky Wajcman, D., Pannain, S. et al.

Nature Medicine

10.1038/s41591-025-03759-8
Public Health & Clinical Best Practices

Public Health & Clinical Best Practices

Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)
Duseja, Ajay et al.

Journal of Clinical and Experimental Hepatology, Volume 13, Issue 2, 273 - 302.

10.1016/j.jceh.2022.11.014
Public Health & Clinical Best Practices

Public Health & Clinical Best Practices

Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association
Cusi, Abdelmalek, Apovian, Balapattabi, Bannuru, et al.

Diabetes Care 2025; dci240094.

10.2337/dci24-0094

See all

Publications

The latest research on SLD, MASLD/MASH, and other related conditions

Public Health & Clinical Best Practices

Public Health & Clinical Best Practices

Clinical utility of the Fibrosis-4 index for predicting mortality in patients with heart failure with or without metabolic dysfunction-associated steatotic liver disease: a prospective cohort study
Boeckmans, Joost et al.

The Lancet Regional Health – Europe, Volume 48, 101153.

10. 1016/j.lanepe.2024. 101153
Public Health & Clinical Best Practices

Public Health & Clinical Best Practices

Decreases in cT1 and liver fat content reflect treatment-induced histological improvements in MASH
Alkhouri, Naim et al.

Journal of Hepatology, Volume 82, Issue 3, 438 - 445.

10.1016/j.jhep.2024.08.031
Public Health & Clinical Best Practices

Public Health & Clinical Best Practices

ALADDIN: A Machine Learning Approach to Enhance the Prediction of Significant Fibrosis or Higher in Metabolic Dysfunction-Associated Steatotic Liver Disease
Alkhouri, Naim, et al.

Am J Gastroenterol. 2025 Mar 27.

10.14309/ajg.0000000000003432

See all

Expert commentary

Critical thinking, current issues, and collective perspectives

See all

Category	Early Bird (before 1 April)	On-site
Private Sector/Industry	495	695
Start-up*	150	200
Healthcare Professional, Academic, Public Health/Professional Association, NGO	100	150
Young Researcher / Trainee / PostDoc / Student / Young Person (under 25) *	50	50
Patient or Patient Representative *	50	50

Explore key resources driving the conversation (and action)

Strategic pillars

Frameworks and policy briefs for local, national and global action

Global agendas

Regional snapshots

Briefing notes

Clinical practice guidelines & position papers

Unified expert perspectives on liver and metabolic health

Publications

The latest research on SLD, MASLD/MASH, and other related conditions

Expert commentary

Critical thinking, current issues, and collective perspectives

Isn’t it time the HealthyNYC campaign becomes more fit for purpose?

5. Strengthen the capacity of community health services to prevent and treat MASLD through social prescribing

5. Leverage electronic health records (EHR) through integrated automated diagnostic tools

4. Increase awareness and education of MASLD/MASH among at-risk groups and healthcare professionals

3. Add MASLD/MASH as an indicator to the list of Key Health System Indicators

2. Create a national MASLD registry, cohort, or observatory

1. Launch a Ministry of Health-led whole-of-government strategy

References

What is ALD?

What is MetALD?

What is MASLD?

What is steatotic liver disease?

Further reading

Registration fees

Criteria for start-ups:

What’s included in your ticket?

Agenda

5 June 2025

6 June 2025

*CARPA